Thursday, 23 Mar 2017

Today's Headlines

NEJM Reviews Psoriatic Arthritis

A comprehensive review of psoriatic arthritis (PsA) was published this week in the NEJM, authored by leaders in the field, Drs. Ritchlin, Colbert and Gladman.

High points from their review inlcuded:

Limited Benefits with Intra-Discal Steroid Injections for Back Pain

A a randomized trial published in Annals of Internal Medicine shows that intradiscal glucocorticoid injection has limited (1 month) efficacy in treating low back pain (LBP) associated with active discopathy, yet decreased over time.

Gadolinium Accumulation with Repeated MRI

Clinical Rheumatology reports that the repeated intravenous administration of gadolinium-based contrast agents (GBCAs), although clinically useful, may be associated with rare toxicity and the uncertain clinical effects of accumulation. 

Lupus Hepatitis and Lupoid Hepatitis Reviewed

SLE-related hepatitis (“lupus hepatitis”) and “lupoid hepatitis” are 2 different diseases. The term "lupoid hepatitis", now known as autoimmune hepatitis (AIH), was first coined in 1959. AIH was initially called “lupoid hepatitis” by MacKay.  A review by Adiga and Nugent reviews, defines and distinguishes between lupus-related hepatitis and lupoid hepatitis.

Cause of Death in Ankylosing Spondylitis

A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.

They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).

The mortality rate of AS remained stable over time.

BLOG

My original agreement with Jack was to review a serious scientific book.  However, half way through one, I was bored, so I went to the library. I'm so glad I did, because I came upon two books, written by Ireland-born physician Patrick Taylor, that continued the tale I'd started years ago about Fingal Flahertie O'Reilly.

 

I had dinner about a month ago in Phoenix with Peter Lipsky, an icon in rheumatology and who requires no introduction to my readers, where we discussed a rambling number of topics both rheumatologic (hence, the experience does qualify for a blog!) and non-rheumatologic.
“It’s unbelievable how much you don’t know about the game you’ve been playing all your life.” - Mickey Mantle

This is going to be my third visit with this patient and I’m not looking forward to it.

In the years to come, the availability of numerous new IL-6 inhibitors it will either complicate treatment decisions, alter existing treatment paradigms, or result in an all-out war against TNF inhibitor dominance. Data, differences and time will tell.
RWCS 2017: Dermatomyositis-Associated Vasculopathy: A Rare Manifestation
/vef/load/1e5d8033a91ec4faa58b6a581c2035e5?width=640&height=365

Daily Download

MTX - Folate Slides from Feb RheumNow Live Vote

RheumNow Live Vote

What drives the decision when/if to stop a bisphosphonate or denosumab?

This month’s Live Vote is being guided by Dr. Kelly Krohn and will focus on the how you use osteoporosis drugs.

Vote!